{"id":725483,"date":"2023-01-24T16:17:30","date_gmt":"2023-01-24T21:17:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/"},"modified":"2023-01-24T16:17:30","modified_gmt":"2023-01-24T21:17:30","slug":"guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/","title":{"rendered":"Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">HOUSTON, Jan.  24, 2023  (GLOBE NEWSWIRE) &#8212; Guardion Health Sciences, Inc (\u201cGuardion\u201d or the \u201cCompany\u201d) (NASDAQ: GHSI) announced today that it has received confirmation from The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing.<\/p>\n<p align=\"justify\">On January 25, 2022, Nasdaq notified Guardion that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive trading days as required by the Listing Rules of Nasdaq. Subsequently, by letter dated January 24, 2023, Nasdaq has determined that for the last 10 consecutive trading days, from January 9, 2023 through January 23, 2023, the closing bid price of Guardion\u2019s common stock has been $1.00 per share or greater, and the Company has therefore regained compliance with Listing Rule 5550(a)(2), and this matter is now closed.<\/p>\n<p>\n        <strong>About Guardion Health Sciences, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Guardion Health Sciences, Inc. (Nasdaq: GHSI), is a clinical nutrition company that offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients. The Company\u2019s combination of expertise and scientifically supported products is the foundation of Guardion\u2019s growing position within the clinical nutrition marketplace. Information and risk factors with respect to Guardion and its business may be obtained in the Company\u2019s filings with the SEC at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VUx8I7cX5t5tUo-43_Y9ZsTsou7kOZcqqfAjQaBAAeA_pCOzNN_ltDnklEHYRaWD4Z5G41xo6ZdMi6riEYahwppZxtxyhA98jPfjcOBbTstJwzAAGB2Mhn87oBAwZzIYyG7FofSdMl8yecDBX_zsB-SgOC4a3-COU_99vkFzdBZv-AcM-smWhpGXAX7v3UqvLEUEiGg1h-kyEduNur6777K2FVsLlcaL_a_8m9t2nmA=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.sec.gov<\/u><\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statement Disclaimer<\/strong>\n      <\/p>\n<p align=\"justify\">With the exception of the historical information contained in this news release, the matters described herein may contain \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions regarding our product development and commercialization efforts, research and development efforts, business, financial condition, results of operations, strategies or prospects, and other similar matters. Statements preceded by, followed by or that otherwise include the words \u201cbelieves,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cprojects,\u201d \u201cestimates,\u201d \u201cplans,\u201d \u201chopes\u201d and similar expressions or future or conditional verbs such as \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cmay\u201d and \u201ccould\u201d are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing.<\/p>\n<p align=\"justify\">These statements are based on management\u2019s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company\u2019s ability to raise sufficient financing to implement its business plan, the impact of the Company\u2019s exploration of strategic alternatives, the integration of new management team members, the implementation of new financial, management, accounting and business software systems, the integration of possible acquisition targets, the impact of the Covid-19 pandemic, supply chain disruptions, inflation and a potential recession on the Company\u2019s business, operations and the economy in general, the Company\u2019s ability to successfully develop and commercialize its proprietary products and technologies, and the Company\u2019s ability to maintain compliance with Nasdaq\u2019s listing requirements.<\/p>\n<p align=\"justify\">Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company\u2019s filings with the SEC, which are available at the SEC\u2019s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>CORE IR<br \/>Scott Arnold<br \/>516-222-2560<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fMCZvjMTtpTYLloXjI7X4anZV8CWQxTp_cw3-LpqVmAO1CO5zricBfaZlUlZ_3T3s3jnE67eXoRaTe6UzSXj5Q==\" rel=\"nofollow noopener\" target=\"_blank\">scotta@coreir.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Relations Contact:<\/strong><br \/>\n        <br \/>Jules Abraham<br \/>Director of Public Relations<br \/>CORE IR<br \/>917-885-7378<br \/>julesa@coreir.com<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTc0MiM1MzcyMjU2IzIxODM2Mjc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzIxNWQxZGEtMmZhNS00NTkxLTgwNWYtOTM0ODViYmYzNmVlLTExOTUxODU=\/tiny\/Guardion-Health-Sciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HOUSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) &#8212; Guardion Health Sciences, Inc (\u201cGuardion\u201d or the \u201cCompany\u201d) (NASDAQ: GHSI) announced today that it has received confirmation from The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing. On January 25, 2022, Nasdaq notified Guardion that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive trading days as required by the Listing Rules of Nasdaq. Subsequently, by letter dated January 24, 2023, Nasdaq has determined that for the last 10 consecutive trading days, from January 9, 2023 through January &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-725483","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) &#8212; Guardion Health Sciences, Inc (\u201cGuardion\u201d or the \u201cCompany\u201d) (NASDAQ: GHSI) announced today that it has received confirmation from The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing. On January 25, 2022, Nasdaq notified Guardion that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive trading days as required by the Listing Rules of Nasdaq. Subsequently, by letter dated January 24, 2023, Nasdaq has determined that for the last 10 consecutive trading days, from January 9, 2023 through January &hellip; Continue reading &quot;Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-24T21:17:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTc0MiM1MzcyMjU2IzIxODM2Mjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements\",\"datePublished\":\"2023-01-24T21:17:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\\\/\"},\"wordCount\":644,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNTc0MiM1MzcyMjU2IzIxODM2Mjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\\\/\",\"name\":\"Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNTc0MiM1MzcyMjU2IzIxODM2Mjc=\",\"datePublished\":\"2023-01-24T21:17:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNTc0MiM1MzcyMjU2IzIxODM2Mjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNTc0MiM1MzcyMjU2IzIxODM2Mjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/","og_locale":"en_US","og_type":"article","og_title":"Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements - Market Newsdesk","og_description":"HOUSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) &#8212; Guardion Health Sciences, Inc (\u201cGuardion\u201d or the \u201cCompany\u201d) (NASDAQ: GHSI) announced today that it has received confirmation from The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing. On January 25, 2022, Nasdaq notified Guardion that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive trading days as required by the Listing Rules of Nasdaq. Subsequently, by letter dated January 24, 2023, Nasdaq has determined that for the last 10 consecutive trading days, from January 9, 2023 through January &hellip; Continue reading \"Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-24T21:17:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTc0MiM1MzcyMjU2IzIxODM2Mjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements","datePublished":"2023-01-24T21:17:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/"},"wordCount":644,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTc0MiM1MzcyMjU2IzIxODM2Mjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/","name":"Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTc0MiM1MzcyMjU2IzIxODM2Mjc=","datePublished":"2023-01-24T21:17:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTc0MiM1MzcyMjU2IzIxODM2Mjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNTc0MiM1MzcyMjU2IzIxODM2Mjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardion-health-sciences-inc-regains-compliance-with-nasdaq-continued-listing-requirements\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/725483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=725483"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/725483\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=725483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=725483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=725483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}